Expanded Testing Reach Affirm MicroGenDX’s broad adoption by over 39,000 physicians and 900,000 patients, plus CAP/CLIA accreditation, highlighting a trusted channel for upsell of additional infectious disease panels, rapid qPCR+NGS tests, and new services to existing hospital and long-term care customers.

Rapid Diagnostic Advantage Leverage the faster turnaround and comprehensive pathogen detection of NGS over culture-based methods to position value in high-stakes clinical settings such as hospitals and long-term care facilities, enabling cross-sell of related panels like PerioDX or emerging Rapid H5 assays.

Strategic Partnerships Capitalize on existing collaborations with notable institutions and industry players (CDC, U.S. Army, Mayo Clinic, NASA) to pursue co-development, white-labeling, or pilot programs with larger health systems and government contractors seeking validated molecular diagnostics.

New Product Opportunities Target expansion opportunities around recent launches such as Rapid H5 and patient-focused access platforms, offering bundled testing solutions, telehealth-compatible workflows, and direct-to-consumer pathways to drive patient-driven demand and expand payer conversations.

Geographic and Facility Growth Utilize the Carbondale facility expansion and ongoing hospital/dental/veterinary adoption to pursue regional lab network partnerships, managed services, and white-label offerings to core care settings, increasing installed base and recurring revenue.